Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives

被引：0
作者：
Bartalucci, Niccolo [1 ,2 ]
Galluzzi, Lorenzo [3 ,4 ,5 ,6 ,7 ]
机构：
[1] Univ Florence, Dept Expt & Clin Med, Florence, Italy
[2] Univ Florence, DENOThe Excellence Ctr, Florence, Italy
[3] Weill Cornell Med Coll, Dept Radiat Oncol, New York, NY 10021 USA
[4] Sandra & Edward Meyer Canc Ctr, New York, NY 10021 USA
[5] Caryl & Israel Englander Inst Precis Med, New York, NY 10021 USA
[6] Yale Sch Med, Dept Dermatol, New Haven, CT 06510 USA
[7] Univ Paris, Paris, France
来源：
CELLULAR AND MOLECULAR ASPECTS OF MYELOPROLIFERATIVE NEOPLASMS - PT A | 2021年 / 365卷
关键词：
INTERNATIONAL PROGNOSTIC SCORE; TYROSINE KINASE JAK2; POLYCYTHEMIA-VERA; ESSENTIAL THROMBOCYTHEMIA; PRIMARY MYELOFIBROSIS; ACTIVATING MUTATION; MPL MUTATIONS; INHIBITOR; RUXOLITINIB; CELLS;
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：IX / XX
页数：12
相关论文
共 120 条
[1]   Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors [J].
Alcantara, Marion ;
Du Rusquec, Pauline ;
Romano, Emanuela .
ONCOIMMUNOLOGY, 2020, 9 (01)
[2]   The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert ;
Thiele, Jurgen ;
Borowitz, Michael J. ;
Le Beau, Michelle M. ;
Bloomfield, Clara D. ;
Cazzola, Mario ;
Vardiman, James W. .
BLOOD, 2016, 127 (20) :2391-2405
[3]   Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I [J].
Arshad, Najla ;
Cresswell, Peter .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2018, 293 (25) :9555-9569
[4]   Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs [J].
Balliu, Manjola ;
Calabresi, Laura ;
Bartalucci, Niccolo ;
Romagnoli, Simone ;
Maggi, Laura ;
Manfredini, Rossella ;
Lulli, Matteo ;
Guglielmelli, Paola ;
Vannucchi, Alessandro Maria .
BLOOD ADVANCES, 2021, 5 (08) :2184-2195
[5]   The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion [J].
Barbui, Tiziano ;
Thiele, Jurgen ;
Gisslinger, Heinz ;
Kvasnicka, Hans Michael ;
Vannucchi, Alessandro M. ;
Guglielmelli, Paola ;
Orazi, Attilio ;
Tefferi, Ayalew .
BLOOD CANCER JOURNAL, 2018, 8 :15
[6]   In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology [J].
Barbui, Tiziano ;
Carobbio, Alessandra ;
Rumi, Elisa ;
Finazzi, Guido ;
Gisslinger, Heinz ;
Rodeghiero, Francesco ;
Randi, Maria Luigia ;
Rambaldi, Alessandro ;
Gisslinger, Bettina ;
Pieri, Lisa ;
Bertozzi, Irene ;
Casetti, Ilaria ;
Pardanani, Animesh ;
Passamonti, Francesco ;
Vannucchi, Alessandro M. ;
Tefferi, Ayalew .
BLOOD, 2014, 124 (19) :3021-3023
[7]   Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis) [J].
Barbui, Tiziano ;
Finazzi, Guido ;
Carobbio, Alessandra ;
Thiele, Juergen ;
Passamonti, Francesco ;
Rumi, Elisa ;
Ruggeri, Marco ;
Rodeghiero, Francesco ;
Randi, Maria Luigia ;
Bertozzi, Irene ;
Gisslinger, Heinz ;
Buxhofer-Ausch, Veronika ;
De Stefano, Valerio ;
Betti, Silvia ;
Rambaldi, Alessandro ;
Vannucchi, Alessandro M. ;
Tefferi, Ayalew .
BLOOD, 2012, 120 (26) :5128-5133
[8]   The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis [J].
Barone, Martina ;
Catani, Lucia ;
Ricci, Francesca ;
Romano, Marco ;
Forte, Dorian ;
Auteri, Giuseppe ;
Bartoletti, Daniela ;
Ottaviani, Emanuela ;
Tazzari, Pier Luigi ;
Vianelli, Nicola ;
Cavo, Michele ;
Palandri, Francesca .
ONCOIMMUNOLOGY, 2020, 9 (01)
[9]   Polycythemia vera: the current status of preclinical models and therapeutic targets [J].
Bartalucci, Niccolo ;
Guglielmelli, Paola ;
Vannucchi, Alessandro M. .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2020, 24 (07) :615-628
[10]   Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in &ITJAK2V617F &ITmutated cells through PP2A/CIP2A axis [J].
Bartalucci, Niccolo ;
Calabresi, Laura ;
Balliu, Manjola ;
Martinelli, Serena ;
Rossi, Maria Caterina ;
Villeval, Jean Luc ;
Annunziato, Francesco ;
Guglielmelli, Paola ;
Vannucchi, Alessandro M. .
ONCOTARGET, 2017, 8 (57) :96710-96724
12345678910